HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada

← catalyst calendar

NCT06386263

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Daiichi Sankyo.

Phase

—

Status

Completed

Study type

Observational

Enrollment

22actual

Sites

Country

Canada

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-04-22

actual

When the study began enrolling

Primary completion

2025-07-07

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2025-07-07

actual

The whole study's end, after follow-up

First posted

2024-04-26

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-08

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Unresectable Breast Cancer
Metastatic Breast Cancer
HER2-low Expressing Breast Cancer
HER2-positive Breast Cancer

Intervention

Drug: Trastuzumab deruxtecan — also filed as T-DXd, Enhertu

Primary outcomes

what the primary-completion date above is the date OF

Early treatment discontinuation rates

measured 3, 6, 9 months

Dose modifications

measured from baseline to treatment discontinuation or the end of PSP, assessed up to 12 months (HER2-positive cohort) and up to 14 months (HER2-low cohort)

Publications

PMID 40976668 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed